BloodCenter of Wisconsin Launches Suite of Tests to Diagnose Atypical Hemolytic Uremic Syndrome - KAUZ-TV: Newschannel 6 Now | Wichita Falls, TX

BloodCenter of Wisconsin Launches Suite of Tests to Diagnose Atypical Hemolytic Uremic Syndrome

Information contained on this page is provided by an independent third-party content provider. WorldNow and this Station make no warranties or representations in connection therewith. If you have any questions or comments about this page please contact pressreleases@worldnow.com.

SOURCE BloodCenter of Wisconsin

New testing approach uses Next Gen Sequencing platform

MILWAUKEE, Jan. 16, 2014 /PRNewswire/ -- BloodCenter of Wisconsin's Diagnostic Laboratories today announced the availability of a comprehensive genetic evaluation using next generation sequencing (NGS) technology for  patients with Atypical Hemolytic Uremic Syndrome (aHUS).  BloodCenter is among the first to offer clinical diagnostics using NGS, providing a dramatically shortened timeline for obtaining test results for this condition.

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/65179-bloodcenter-wisconsin-launches-tests-atypical-hemolytic-uremic-syndrome

aHUS is a genetic, rare and life-threatening disease clinically characterized by anemia, coagulation defects, and organ dysfunction, most often in the form of kidney disease.

BloodCenter's aHUS tests using NGS are a breakthrough for physicians and their patients who currently wait three to six months for a genetic test result surrounding this life-threatening disease. Providing test results in a timely manner allows physicians to confidently prescribe appropriate care. With BloodCenter's NGS approach, test results are provided within 28 days.

"This is the first of many tests for which BloodCenter plans to use NGS technology," said Matthew Anderson, M.D., Ph.D., medical director for BloodCenter of Wisconsin's Diagnostic Laboratories. "Application of this technology will revolutionize how genetic information is utilized for patient care."

Approximately sixty percent of aHUS cases are diagnosed in children, with most having their first acute episode before 2 years of age. Within the first year after diagnosis, sixty-five percent of all patients have permanent kidney damage, require kidney dialysis, or die.

There are three possible treatments for patients with aHUS:  plasma exchange therapy, expensive drug infusions, or kidney transplantation. "BloodCenter's diagnostic solution provides physicians with critical information to better manage the treatment of their patients," said Anderson. 

BloodCenter's Diagnostic Laboratories help physicians provide clinical care to patients worldwide, fostering better understanding and treatment options for patients with difficult-to-diagnose diseases. In addition, the laboratories collaborate with other institutions and industry partners to bring new diagnostic testing and treatment options to patient care.

About BloodCenter of Wisconsin
BloodCenter of Wisconsin is a not-for-profit organization that specializes in blood services, organ, tissue and marrow donation, diagnostic testing, medical services and leading-edge research. BloodCenter of Wisconsin is the only provider of blood to hospitals in 29 Wisconsin counties as well as providing support to hospitals and patients across the country. BloodCenter of Wisconsin advances patient care by delivering life-saving solutions grounded in unparalleled medical and scientific expertise. For more information, visit www.bcw.edu.

Advancing patient care as a pioneering leader in science and medicine

 

BloodCenter of Wisconsin aHUS Diagnostic Work-up Algorithm

 

BloodCenter of Wisconsin aHUS Testing Brochure An integrated, innovative suite of tests

To view the multimedia assets associated with this release, please click: http://www.multivu.com/mnr/65179-bloodcenter-wisconsin-launches-tests-atypical-hemolytic-uremic-syndrome

Contact:
Fay Spano 414-937-6124
Fay.Spano@bcw.edu

©2012 PR Newswire. All Rights Reserved.